From: A clinical tool to predict Plasmodium vivax recurrence in Malaysia
Patient characteristic | n | Percentage (%) |
---|---|---|
Age, years, (mean, 95% CI) (range) | 28.0, 27.3–28.7 | 2 weeks −80 years |
Gender (n) (%) | ||
Male | 1558 | 76.2 |
Female | 486 | 23.8 |
Nationality (n) (%) | ||
Malaysian | 1310 | 64.1 |
Non-Malaysian | 734 | 36.0 |
WHO Region (n) (%) | ||
Africa | 1 | 0.1 |
South-East Asia | 522 | 25.5 |
Western Pacific | 1367 | 66.8 |
Eastern Mediterranean | 152 | 7.4 |
Unknown | 2 | 0.1 |
Glucose-6-phosphate-dehydrogenase (G6PD) (n) (%) | ||
Deficient | 126 | 6.2 |
Normal | 1252 | 61.2 |
Unknown | 666 | 32.6 |
Pregnancy (n) (%), total = 486 | ||
No | 448 | 92.2 |
Yes | 38 | 7.8 |
Case locality | ||
Urban | 366 | 17.9 |
Rural | 1090 | 53.5 |
Unknown | 588 | 28.7 |
Status of case locality (n) (%) | ||
Free | 829 | 40.6 |
Prone | 164 | 8 |
Problematic | 1033 | 50.5 |
Unknown | 18 | 0.9 |
Disease characteristic | ||
Length of stay (days) (mean, 95% CI) (range) | 6.1, 5.9–6.3 | 0–45 |
Previous malaria infection (n) (%) | ||
No | 1418 | 69.4 |
Yes | 454 | 22.2 |
Unknown | 172 | 8.4 |
Presence of gametocyte during admission (n) (%) | ||
Positive | 808 | 39.5 |
Negative | 579 | 28.3 |
Unknown | 657 | 32.1 |
Gametocyte/μL on admission (mean, 95% CI) (range) | 857.4, 741–972 | 1–19,642 |
Asexual/μL on admission (mean, 95% CI) (range) | 6402, 5458–7346 | 1–732,200 |
Week onset (week) (mean, 95% CI) (range) | 20.53, 19–21 | 0–52 |
Severity (n) (%) | ||
Non-severe | 1961 | 95.9 |
Severe | 55 | 2.7 |
Unknown | 28 | 1.4 |
Malaria transmission type (n) (%) | ||
Imported | 739 | 36.2 |
Indigenous | 1195 | 58.5 |
Introduced | 47 | 2.3 |
Relapse before | 63 | 3.1 |
Treatment characteristic | ||
Type of antimalarial drugs (n) (%) | ||
CQ plus PQ | 1373 | 67.2 |
ACT plus PQ | 669 | 32.7 |
No treatment | 2 | 0.1 |
Status of PQ treatment (n) (%) | ||
Complete | 2014 | 98.5 |
Incomplete | 14 | 0.7 |
Unknown | 16 | 0.8 |